Adaptimmune Therapeutics Stock Forecast - Naive Prediction

ADAP Stock  USD 0.64  0.02  3.03%   
The Naive Prediction forecasted value of Adaptimmune Therapeutics Plc on the next trading day is expected to be 0.57 with a mean absolute deviation of 0.03 and the sum of the absolute errors of 2.16. Adaptimmune Stock Forecast is based on your current time horizon. Although Adaptimmune Therapeutics' naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Adaptimmune Therapeutics' systematic risk associated with finding meaningful patterns of Adaptimmune Therapeutics fundamentals over time.
  
As of 11/22/2024, Asset Turnover is likely to grow to 0.22, while Inventory Turnover is likely to drop 71.90. . As of 11/22/2024, Common Stock Shares Outstanding is likely to drop to about 129.5 M. In addition to that, Net Loss is likely to grow to about (141.5 M).

Adaptimmune Therapeutics Cash Forecast

Forecasting financial indicators like cash flow involves analysts applying various statistical methods, techniques, and algorithms. These tools reveal hidden trends within the Adaptimmune Therapeutics' financial statements to estimate their effects on upcoming price movements.
 
Cash  
First Reported
2013-06-30
Previous Quarter
211.8 M
Current Value
116.7 M
Quarterly Volatility
56.1 M
 
Yuan Drop
 
Covid
A naive forecasting model for Adaptimmune Therapeutics is a special case of the moving average forecasting where the number of periods used for smoothing is one. Therefore, the forecast of Adaptimmune Therapeutics Plc value for a given trading day is simply the observed value for the previous period. Due to the simplistic nature of the naive forecasting model, it can only be used to forecast up to one period.

Adaptimmune Therapeutics Naive Prediction Price Forecast For the 23rd of November

Given 90 days horizon, the Naive Prediction forecasted value of Adaptimmune Therapeutics Plc on the next trading day is expected to be 0.57 with a mean absolute deviation of 0.03, mean absolute percentage error of 0, and the sum of the absolute errors of 2.16.
Please note that although there have been many attempts to predict Adaptimmune Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Adaptimmune Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).

Adaptimmune Therapeutics Stock Forecast Pattern

Backtest Adaptimmune TherapeuticsAdaptimmune Therapeutics Price PredictionBuy or Sell Advice 

Adaptimmune Therapeutics Forecasted Value

In the context of forecasting Adaptimmune Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Adaptimmune Therapeutics' downside and upside margins for the forecasting period are 0.01 and 5.14, respectively. We have considered Adaptimmune Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Market Value
0.64
0.57
Expected Value
5.14
Upside

Model Predictive Factors

The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Adaptimmune Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Adaptimmune Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.
AICAkaike Information Criteria113.7154
BiasArithmetic mean of the errors None
MADMean absolute deviation0.0349
MAPEMean absolute percentage error0.0433
SAESum of the absolute errors2.1625
This model is not at all useful as a medium-long range forecasting tool of Adaptimmune Therapeutics Plc. This model is simplistic and is included partly for completeness and partly because of its simplicity. It is unlikely that you'll want to use this model directly to predict Adaptimmune Therapeutics. Instead, consider using either the moving average model or the more general weighted moving average model with a higher (i.e., greater than 1) number of periods, and possibly a different set of weights.

Predictive Modules for Adaptimmune Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Adaptimmune Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.030.665.40
Details
Intrinsic
Valuation
LowRealHigh
0.091.876.61
Details
9 Analysts
Consensus
LowTargetHigh
5.085.586.19
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Adaptimmune Therapeutics. Your research has to be compared to or analyzed against Adaptimmune Therapeutics' peers to derive any actionable benefits. When done correctly, Adaptimmune Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Adaptimmune Therapeutics.

Other Forecasting Options for Adaptimmune Therapeutics

For every potential investor in Adaptimmune, whether a beginner or expert, Adaptimmune Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Adaptimmune Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Adaptimmune. Basic forecasting techniques help filter out the noise by identifying Adaptimmune Therapeutics' price trends.

View Adaptimmune Therapeutics Related Equities

 Risk & Return  Correlation

Adaptimmune Therapeutics Technical and Predictive Analytics

The stock market is financially volatile. Despite the volatility, there exist limitless possibilities of gaining profits and building passive income portfolios. With the complexity of Adaptimmune Therapeutics' price movements, a comprehensive understanding of forecasting methods that an investor can rely on to make the right move is invaluable. These methods predict trends that assist an investor in predicting the movement of Adaptimmune Therapeutics' current price.

Adaptimmune Therapeutics Market Strength Events

Market strength indicators help investors to evaluate how Adaptimmune Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Adaptimmune Therapeutics shares will generate the highest return on investment. By undertsting and applying Adaptimmune Therapeutics stock market strength indicators, traders can identify Adaptimmune Therapeutics Plc entry and exit signals to maximize returns.

Adaptimmune Therapeutics Risk Indicators

The analysis of Adaptimmune Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Adaptimmune Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting adaptimmune stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.

Pair Trading with Adaptimmune Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Adaptimmune Stock

  0.79VRAX Virax Biolabs GroupPairCorr
  0.76DYN Dyne TherapeuticsPairCorr

Moving against Adaptimmune Stock

  0.85EWTX Edgewise TherapeuticsPairCorr
  0.84PRAX Praxis Precision MedPairCorr
  0.83AMLX Amylyx PharmaceuticalsPairCorr
  0.7VRDN Viridian TherapeuticsPairCorr
  0.7AKRO Akero TherapeuticsPairCorr
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Adaptimmune Stock Analysis

When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.